A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction.

Blayne WelkDuane HicklingMary McKibbonSidney RadomskiKaren Ethans

Published in: Neurourology and urodynamics (2018)

Among patients with SCI or MS, we demonstrated non-significant trends towards improvement in some urodynamic parameters with mirabegron 50 mg compared to placebo, and a significantly lower neurogenic bladder symptom burden.

Keyphrases

urinary tract
spinal cord injury
double blind
mass spectrometry
multiple sclerosis
oxidative stress
ms ms
study protocol
open label
randomized controlled trial
phase iii